Renaissance BioScience Corp. and Timeless Capital Corp. Enter into Letter of Intent

Calgary, Alberta--(Newsfile Corp. - January 25, 2023) - Timeless Capital Corp. (TSXV: TLC.P) ("Timeless" or the "Company"), a capital pool company as defined under TSX Venture Exchange ("TSXV" or the "Exchange") policies, is pleased to announce it has entered into a non-binding letter of intent dated January 25, 2023 (the "LOI") with Renaissance BioScience Corp. ("Renaissance"), a corporation organized under the laws of British Columbia, in respect of a proposed business combination that would result in the reverse take-over of Timeless by Renaissance to form the resulting issuer (the "Resulting Issuer") which will continue on the business of Renaissance (the "Transaction"). Timeless intends that the Transaction will constitute its Qualifying Transaction, as such term is defined in the policies of the Exchange.

About Renaissance

Renaissance is a leading bioengineering company based in Vancouver, British Columbia whose platform technologies are used to develop innovative, market-ready, functional microorganisms that provide cost-effective solutions to a broad range of environmental, health and industrial efficiency problems. Renaissance technologies create products for multiple end-use industries, including food & beverage, agriculture crop protection, animal and human health and energy.

Summary of Proposed Transaction

The material terms and conditions outlined in the LOI are non-binding on the parties and the LOI is, among other things, conditional on the execution of a definitive agreement (the "Definitive Agreement") to be negotiated between the parties.

Renaissance currently has 25,103,920 issued and outstanding common shares (the "Renaissance Shares"), and it is anticipated that the Renaissance Shares will be split on a 3 for 1 basis prior to the Transaction. There are currently 7,000,000 common shares of Timeless ("Timeless Shares") issued and outstanding and up to an additional 3,000,000 Timeless Shares may be issued pursuant to the recently announced private placement. Pursuant to the Transaction, Timeless will effect a share consolidation (the "Consolidation") on the basis of one new Timeless Share for each 2.14 previous Timeless Shares issued and outstanding. Pursuant to the Transaction, one post-Consolidation Timeless Share will be issued in exchange for each Renaissance Share issued and outstanding. As a result of the Transaction, any outstanding convertible securities of Renaissance will be adjusted accordingly or replacement securities issued in the Resulting Issuer.

The LOI provides for Timeless to pay a $25,000 non-refundable deposit to Renaissance. In addition, it requires Timeless to reimburse Renaissance for expenses relating to the Transaction in accordance with Exchange Policy 2.4 – Capital Pool Companies.

It is anticipated that the Resulting Issuer will continue the business of Renaissance under a new name which will include "Renaissance BioScience", or such other name as the board of directors of the Resulting Issuer shall determine and as may be approved by the TSXV (the "Name Change"). Upon completion of the Transaction, it is anticipated that the board of directors of the Resulting Issuer will be comprised of one nominee of Timeless and at least four nominees of Renaissance and that the officers of the Resulting Issuer shall be nominees of Renaissance.

Certain common shares of the Resulting Issuer to be issued pursuant to the Transaction are expected to be subject to restrictions on resale or escrow under the policies of the TSXV, including the securities to be issued to "Principals" (as defined under TSXV policies), which will be subject to the escrow requirements of the Exchange.

Completion of the Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange requirements, majority of the minority shareholder approval. Where applicable, the Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Transaction will be completed as proposed or at all. In addition, the Transaction is conditional upon the negotiation and execution of the Definitive Agreement, each of Timeless and Renaissance being satisfied with the results of its due diligence review of the other party, completion of the Concurrent Financing (as described below), receipt of Timeless and Renaissance board approval for the Transaction, receipt of Renaissance shareholder approval of the Transaction, receipt of Timeless shareholder approval for all necessary matters, including the Name Change and Consolidation, and Timeless and Renaissance obtaining all necessary consents, orders and regulatory approvals, including the approval of the Exchange, and other customary conditions.

Concurrent Financing

The LOI contemplates that prior to the closing of the Transaction, Renaissance will complete a brokered equity private placement for minimum gross proceeds of $5,000,000 ("Concurrent Financing"). Further terms relating to the Concurrent Financing, including the maximum size of the offering and the pricing thereof, shall be determined by Renaissance and disclosed in a future press release.

Sponsorship

Timeless intends to make an application for exemption from the sponsorship requirements of the TSXV in connection with the Transaction, however there is no assurance that the TSXV will exempt Timeless from all or part of applicable sponsorship requirements.

Additional Information

Additional information concerning the Transaction, Timeless, Renaissance and the Resulting Issuer, including financial information of Renaissance, will be provided in subsequent news releases and in Timeless' Filing Statement to be filed in connection with the Transaction, which will be available under Timeless' SEDAR profile at www.sedar.com.

Upon closing of the Transaction, the Resulting Issuer expects to list as a Tier 1 Life Sciences issuer on the Exchange.

The Transaction will not constitute a "Non-Arm's Length Qualifying Transaction" (as such term is defined in the policies of the TSXV). Accordingly, it is not anticipated that the Transaction will be subject to the approval of the Timeless shareholders.

In accordance with the policies of the TSXV, the Timeless Shares are currently halted from trading and will remain so until such time as the TSXV determines, which, depending on the policies of the TSXV, may not occur until completion of the Transaction.

About Timeless

Timeless completed its initial public offering in October 2018. The Timeless Shares are listed for trading on the TSXV under the stock symbol "TLC.P". Timeless has not commenced commercial operations and has no assets other than cash. Timeless was incorporated under the laws of the Province of Alberta.

Further Information

Timeless Capital Corp.
Fahim Gadallah, CEO
Phone: (604) 248-2080
Email: [email protected]

Renaissance BioScience Corp.
Steve Campbell, Communications and Public Relations
Phone: (604) 888-5267
Email: [email protected]

Completion of the Transaction is subject to a number of conditions, including without limitation, Exchange acceptance and obtaining all shareholder approvals. There can be no assurance that the Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the Filing Statement to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

There is no assurance that a Definitive Agreement will be successfully negotiated or entered into and there is no assurance that the Concurrent Financing will be completed.

The TSXV has in no way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this press release.

All information contained in this press release with respect to Renaissance and Timeless was supplied by the parties respectively, for inclusion herein, without independent review by the other party, and each party and its directors and officers have relied on the other party for any information concerning the other party.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws, unless an exemption from such registration is available.

Forward-Looking Information

This press release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this press release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected" "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts". "estimates", "believes" or intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could, "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this press release, forward-looking statements relate, among other things, to: the Transaction and certain terms and conditions thereof; the business of Renaissance, the Concurrent Financing; the split of the Renaissance Shares and the ratio thereof; the Consolidation of Timeless Shares and the ratio thereof; the Name Change; the exchange ratio for the Renaissance securities; TSXV sponsorship requirements and intended application for exemption therefrom; shareholder, director and regulatory approvals; and future press releases and disclosure. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive shareholder, director or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Except as required by law, neither Timeless nor Renaissance assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/152538